CA
ABBV icon

Centerpoint Advisors’s AbbVie ABBV Stock Holding History

Centerpoint Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$297K Sell
1,182
-296
-20% -$63.7K 0.08% 74
2026
Q1 		$321K Sell
1,478
-297
-17% -$65.9K 0.1% 67
2025
Q4 		$405K Sell
1,775
-4
-0.2% -$911 0.12% 63
2025
Q3 		$412K Buy
1,779
+84
+5% +$17.1K 0.13% 64
2025
Q2 		$315K Buy
1,695
+12
+0.7% +$2.23K 0.11% 68
2025
Q1 		$353K Buy
1,683
+3
+0.2% +$583 0.13% 62
2024
Q4 		$298K Sell
1,680
-138
-8% -$25.4K 0.1% 71
2024
Q3 		$359K Sell
1,818
-96
-5% -$17.9K 0.12% 61
2024
Q2 		$328K Sell
1,914
-149
-7% -$24.7K 0.12% 65
2024
Q1 		$376K Buy
2,063
+328
+19% +$56.5K 0.14% 56
2023
Q4 		$269K Buy
1,735
+118
+7% +$17.2K 0.11% 71
2023
Q3 		$241K Buy
1,617
+4
+0.2% +$587 0.1% 81
2023
Q2 		$217K Sell
1,613
-134
-8% -$19.6K 0.09% 83
2023
Q1 		$278K Buy
1,747
+325
+23% +$49.7K 0.12% 74
2022
Q4 		$230K Buy
1,422
+11
+0.8% +$1.69K 0.11% 79
2022
Q3 		$189K Buy
1,411
+904
+178% +$130K 0.1% 80
2022
Q2 		$78K Buy
507
+113
+29% +$17.3K 0.04% 122
2022
Q1 		$64K Buy
394
+3
+0.8% +$436 0.03% 134
2021
Q4 		$53K Buy
391
+3
+0.8% +$354 0.02% 131
2021
Q3 		$42K Buy
388
+43
+12% +$4.91K 0.02% 134
2021
Q2 		$39K Buy
+345
New +$38.9K 0.02% 139
2018
Q4 		– Sell
-675
Closed -$64K – 250
2018
Q3 		$64K Buy
675
+570
+543% +$54.1K 0.05% 87
2018
Q2 		$10K Buy
105
+39
+59% +$3.81K 0.01% 176
2018
Q1 		$6K Buy
+66
New +$7.25K 0.01% 173

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Centerpoint Advisors's ABBV Position: Q2 2026 in Review

Centerpoint Advisors reduced its AbbVie (ABBV) stake by 20% in Q2 2026, selling an estimated $63.7K and leaving 1,182 shares worth $297K. The position accounts for 0.08% of the portfolio, ranked #74.

Centerpoint Advisors first reported a position in ABBV in Q1 2018 and has held it in 24 quarters since. The position peaked at $412K in Q3 2025. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Centerpoint Advisors held 1,182 shares of AbbVie worth $297K as of Q2 2026.
  • Centerpoint Advisors sold 296 AbbVie shares in Q2 2026, an estimated $63.7K.
  • AbbVie made up 0.08% of Centerpoint Advisors's portfolio in Q2 2026, its #74 holding.
  • Centerpoint Advisors first reported a position in AbbVie in Q1 2018 and has held it in 24 quarters since.
  • Centerpoint Advisors's AbbVie position peaked at $412K in Q3 2025.
  • 4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Centerpoint Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.